Cover Image
市場調查報告書

製藥產業上季度交易分析:聯盟、許可證、投資、M&A與趨勢

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016

出版商 GlobalData 商品編碼 242636
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
製藥產業上季度交易分析:聯盟、許可證、投資、M&A與趨勢 Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016
出版日期: 2016年12月01日 內容資訊: 英文 133 Pages
簡介

本報告提供全球製藥、醫療市場相關資料每季相關調查分析,尤其是以聯盟、許可證、M&A、資金籌措相關主要資料與趨勢分析為焦點,提供過去5季交易數量交易類型/市場區隔/各地區比較與交易額,製藥、醫療產業的主要創業投資(VC)和顧問公司最新資訊,為您概述為以下內容。

第1章 目錄

第2章 全球製藥、醫療市場:交易摘要

  • M&A
  • 股票上市交易
  • 創業投資交易
  • 私募股權的發行

第3章 全球製藥、醫療市場:聯盟交易

  • 聯盟交易
  • 聯盟交易:各治療領域
  • 聯盟交易:預付款/階段性付款、各交易金額
  • 聯盟交易:各治療領域,預付款/階段性付款、各交易金額
  • 聯盟交易:各階段,交易數量、交易額
  • 聯盟交易:各階段,預付款/階段性付款、各交易金額

第4章 全球製藥、醫療市場:授權合約

  • 授權合約
  • 授權合約交易:預付款/階段性付款、交易額
  • 授權合約交易:各治療領域,總交易額
  • 授權合約交易:各治療領域,預付款vs.階段性付款
  • 授權合約交易:各階段,總交易額
  • 授權合約交易:各階段,預付款vs.階段性付款

第5章 全球製藥、醫療市場:M&A財務分析

  • 平均交易額vs.中間交易額
  • 被收購企業的平均股票價格收益
  • 被收購企業的平均EV/EBITA
  • 每項營業利益的平均交易額
  • 每股的平均交易額vs.每股的平均市場價格
  • 每股的平均交易額vs.每股的平均賬面價格
  • 每銷售的平均交易額

第6章 全球製藥、醫療市場:交易摘要(各治療領域)

  • 腫瘤
  • 中樞神經系統
  • 感染疾病
  • 免疫系
  • 代謝障礙
  • 心血管系統
  • 消化管
  • 皮膚科
  • 呼吸系統
  • 眼科

第7章 交易摘要(各地區)

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 全球製藥、醫療市場:主要的投資顧問公司

  • M&A:過去1年
  • 股票上市:過去1年

第9章 附錄

第10章 其他資訊

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDPH0503QD

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2016 15

  • 2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2016 15
  • 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2016 17
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2016 18
  • 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19
    • 2.4.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 19
    • 2.4.2 Pfizer Acquires Medivation in Tender Offer 20
    • 2.4.3 Shire Raises USD12.1 Billion in Public Offering of Notes 21
    • 2.4.4 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 21
    • 2.4.5 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 22

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2016 23
    • 3.1.1 Top M&A Deals in Q3 2016 24
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2015 - Q3 2016 25
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2016 26
    • 3.2.1 Top Initial Public Offerings in Q3 2016 27
    • 3.2.2 Top Secondary Offerings in Q3 2016 27
    • 3.2.3 Top PIPE Deals in Q3 2016 28
    • 3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2015 - Q3 2016 28
  • 3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2016 30
    • 3.3.1 Top Venture Financing Deals in Q3 2016 31
    • 3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2015 - Q3 2016 33
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2015 - Q3 2016 35
    • 3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36
  • 3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2016 37
    • 3.4.1 Top Private Equity Deals in Q3 2016 38
    • 3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2015 - Q3 2016 39

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2015 - Q3 2016 42
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 44
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2016 45
    • 4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46
    • 4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2016 46
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 47
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 49
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 50
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 52

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2016 54

  • 5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2016 54
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2016 57
    • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2016 58
    • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2016 58
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2015 - Q3 2016 59
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 61
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 63
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 64
  • 5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 66

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 68

  • 6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2015 - Q3 2016 68
  • 6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2015 - Q3 2016 70
  • 6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71
  • 6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2015 - Q3 2016 72
  • 6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2015 - Q3 2016 73
  • 6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 75

  • 7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2016 75
    • 7.1.1 Oncology - Deals of the Quarter 76
  • 7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2016 79
    • 7.2.1 Central Nervous System - Deals of the Quarter 80
  • 7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2016 84
    • 7.3.1 Infectious Disease - Deals of the Quarter 85
  • 7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2016 87
    • 7.4.1 Immunology - Deals of the Quarter 88
  • 7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2016 90
    • 7.5.1 Metabolic Disorders - Deals of the Quarter 91
  • 7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2016 93
    • 7.6.1 Cardiovascular - Deals of the Quarter 94
  • 7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2016 97
    • 7.7.1 Gastrointestinal - Deals of the Quarter 98
  • 7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2016 100
    • 7.8.1 Ophthalmology - Deals of the Quarter 101
  • 7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2016 103
    • 7.9.1 Respiratory - Deals of the Quarter 104
  • 7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2016 107
    • 7.10.1 Dermatology - Deals of the Quarter 108

8 Deal Summary by Geography 111

  • 8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2016 111
    • 8.1.1 North America - Deals of the Quarter 112
  • 8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2016 115
    • 8.2.1 Europe - Deals of the Quarter 116
  • 8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2016 118
    • 8.3.1 Asia-Pacific - Deals of the Quarter 119
  • 8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2016 121
    • 8.4.1 Rest of the World - Deals of the Quarter 122

9 Pharmaceuticals & Healthcare, Global, Top Advisors 124

  • 9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2015 - Q3 2016 124
  • 9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2015 - Q3 2016 126

10 Appendix 128

11 Further Information 130

  • 11.1 Methodology 130
  • 11.2 About GlobalData 131
  • 11.3 Disclosure information 132
  • 11.4 Disclaimer 132

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 16
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2016 18
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 24
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2016 24
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2015 - Q3 2016 25
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 27
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2016 27
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2016 27
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2016 28
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 29
  • Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 31
  • Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2016 31
  • Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2016 33
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 34
  • Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 35
  • Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36
  • Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 38
  • Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2016 38
  • Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 39
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 41
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 43
  • Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 45
  • Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 45
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2016 46
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 48
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 51
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 53
  • Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 55
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 57
  • Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2016 57
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2016 58
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2016 58
  • Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 60
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2015 - Q3 2016 62
  • Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 65
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 67
  • Table 39: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2015 - Q3 2016 69
  • Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2015 - Q3 2016 70
  • Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71
  • Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2015 - Q3 2016 72
  • Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2015 - Q3 2016 73
  • Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74
  • Table 45: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 76
  • Table 46: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 80
  • Table 47: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 85
  • Table 48: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 88
  • Table 49: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 91
  • Table 50: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 94
  • Table 51: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 98
  • Table 52: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 101
  • Table 53: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 104
  • Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 108
  • Table 55: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 112
  • Table 56: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 116
  • Table 57: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 119
  • Table 58: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 122
  • Table 59: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 125
  • Table 60: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 127
  • Table 61: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q3 2015-Q3 2016 128

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 15
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2016 17
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2016 18
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 23
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2015 - Q3 2016 25
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 26
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2015 - Q3 2016 28
  • Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 30
  • Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2016 32
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2016 32
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2015 - Q3 2016 33
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 35
  • Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 37
  • Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2015 - Q3 2016 39
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 40
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 42
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 44
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 47
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 49
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 50
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 52
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 54
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 59
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 61
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 63
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 64
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 66
  • Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2015 - Q3 2016 68
  • Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2015 - Q3 2016 70
  • Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71
  • Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2015 - Q3 2016 72
  • Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2015 - Q3 2016 73
  • Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74
  • Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 75
  • Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 79
  • Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 84
  • Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 87
  • Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 90
  • Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 93
  • Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 97
  • Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 100
  • Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 103
  • Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 107
  • Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 111
  • Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 115
  • Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 118
  • Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 121
  • Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 124
  • Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 126
Back to Top